A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2009-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-008-0047-9PMID 18483853
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Health Utilities Using the EQ-5D in Studies of Cancer

  2012cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

  2008cited by this paper
• Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group.

  2006cited by this paper
• Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.

  2006cited by this paper
• Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.

  2005cited by this paper
• Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer.

  2005cited by this paper
• A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation

  2005cited by this paper
• Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group.

  2004cited by this paper
• A single European currency for EQ-5D health states

  2003cited by this paper
• Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer.

  2001cited by this paper
• Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study.

  2001cited by this paper
• A phase II study of paclitaxel plus carboplatin as first‐line chemotherapy for women with metastatic breast carcinoma

  2000cited by this paper
• Docetaxel and Gemcitabine in Anthracycline-Resistant Advanced Breast Cancer: A Hellenic Cooperative Oncology Group Phase II Study

  2000cited by this paper
• Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.

  1999cited by this paper
• First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group.

  1998cited by this paper
• Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.

  1998cited by this paper
• CONSORT: an evolving tool to help improve the quality of reports of randomized controlled trials. Consolidated Standards of Reporting Trials.

  1998cited by this paper
• Disease of the breast

  1998cited by this paper
• Quality of life and pharmacoeconomics in clinical trials

  1996cited by this paper
• An Introduction to the Bootstrap

  1995cited by this paper
• Monographs on statistics and applied probability

  1990cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• [Treatment of metastatic breast cancer].

  1986influential reference
• Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research.

  1983cited by this paper
• Random-effects models for longitudinal data.

  1982cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper
• Creatinine Clearance: Bedside Estimate

  1973cited by this paper
• Letter: Creatinine clearance: bedside estimate.

  1973cited by this paper

• Inhibition of p38-MK2 pathway enhances the efficacy of microtubule inhibitors in breast cancer cells

  2025cites this paper
• Alternative Agents to Colcemid for Obtaining High-Quality Metaphase Spreads

  2025cites this paper
• Paclitaxel resistance in breast cancer: Current challenges and recent advanced therapeutic strategies.

  2025cites this paper
• CENP-E inhibition induces chromosomal instability and synergizes with diverse microtubule-targeting agents in breast cancer.

  2024cites this paper
• Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations.

  2024cites this paper
• The reckoning of chromosomal instability: past, present, future

  2024cites this paper
• Inhibition of p38-MK2 pathway enhances the efficacy of microtubule inhibitors in breast cancer cells

  2024cites this paper
• Caspase-mediated AURKA cleavage at Asp132 is essential for paclitaxel to elicit cell apoptosis

  2024cites this paper
• Diverse microtubule-targeted anticancer agents kill cells by inducing chromosome missegregation on multipolar spindles

  2023cites this paper
• A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer

  2023cites this paper
• A Systematic Literature Review of Health Utility Values in Breast Cancer

  2022cites this paper
• Anti-tumor pharmacology of natural products targeting mitosis

  2022cites this paper
• Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel

  2021cites this paper
• Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non–Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors

  2020cites this paper
• Role of TDM‐based dose adjustments for taxane anticancer drugs

  2020cites this paper
• Platinum-containing regimens for triple-negative metastatic breast cancer.

  2020cites this paper
• Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.

  2018cites this paper
• This is a repository copy of Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials.

  2018cites this paper
• Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis

  2018cites this paper
• Platinum-containing regimens for metastatic breast cancer.

  2017cites this paper
• Final Results of the Randomized Phase II NorCap‐CA223 Trial Comparing First‐Line All‐Oral Versus Taxane‐Based Chemotherapy for HER2‐Negative Metastatic Breast Cancer

  2017cites this paper
• Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review

  2017influential citation
• A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

  2016cites this paper
• Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?

  2016cites this paper
• Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials.

  2016cites this paper
• Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.

  2016cites this paper
• Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.

  2016cites this paper
• Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer

  2016cites this paper
• Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials

  2016cites this paper
• Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.

  2016cites this paper
• A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer

  2015cites this paper
• Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis

  2015cites this paper
• Management of Metastatic Breast Cancer

  2015cites this paper
• Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer

  2015cites this paper
• Defining the Survival Benchmark for Breast Cancer Patients with Systemic Relapse

  2015cites this paper
• Features of aggressive breast cancer.

  2015cites this paper
• Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer

  2014cites this paper
• Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression

  2014cites this paper
• Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature

  2014cites this paper
• Paclitaxel, Carboplatin, and Trastuzumab

  2014cites this paper
• Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial

  2014cites this paper
• Chemotherapy‐induced peripheral neurotoxicity: A critical analysis

  2013cites this paper
• Current methods for the assessment and management of taxane-related neuropathy.

  2013cites this paper
• Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.

  2013cites this paper
• Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review.

  2013cites this paper
• Original article Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

  2013cites this paper
• The Role of Paclitaxel Albumin-Stabilized Nanoparticle Formulation (Nab-Paclitaxel) in the Treatment of Breast Cancer: A Short Review

  2013cites this paper
• Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials

  2013cites this paper
• Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

  2013cites this paper
• Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial

  2013cites this paper
• Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study

  2012cites this paper
• Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

  2012cites this paper
• Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer

  2012cites this paper
• Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer

  2012cites this paper
• Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.

  2011cites this paper
• The efficacy of HER 2-targeted agents in metastatic breast cancer : a meta-analysis

  2011cites this paper
• Ixabepilone for the treatment of breast cancer

  2011cites this paper
• The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.

  2011cites this paper
• Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.

  2011cites this paper
• Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.

  2011cites this paper
• Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies

  2011cites this paper
• A literature-based meta-analysis taxane-based doublet versus single-agent taxane chemotherapy in patients with advanced breast cancer

  2011cites this paper
• Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.

  2011cites this paper
• Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009).

  2011cites this paper
• Quality of Life of Patients with Metastatic Breast Cancer Treated with Epirubicin and Docetaxel

  2011cites this paper
• First-Line Chemotherapy with Anthracycline and Taxane Combination in Metastatic Breast Cancer. Detection of bone metastases with TRACP 5b

  2011cites this paper
• How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.

  2011cites this paper
• Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials

  2011cites this paper
• Trastuzumab et lapatinib dans la prise en charge du cancer du sein HER2 positif

  2011cites this paper
• Cancer Chemotherapy Update Paclitaxel, Carboplatin, and Trastuzumab

  2011cites this paper
• A review and meta-analysis of health state utility values in breast cancer

  2010cites this paper
• Stratégies thérapeutiques des cancers du sein métastatiques : RH+ HER2−. Hormonothérapies, chimiothérapies (monochimiothérapies séquentielles ou polychimiothérapies concomitantes ?), antiangiogéniques

  2010cites this paper
• Metastatic Breast Cancer

  2010cites this paper
• Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.

  2010cites this paper
• Fifteen-year trends in metastatic breast cancer survival in Greece

  2010cites this paper
• Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis.

  2010cites this paper
• PCN13 TAXANE USE AND NEUROPATHY IN EARLY STAGE BREAST CANCER PATIENTS – RESULTS FROM A US COMMUNITY ONCOLOGY CENTER

  2010cites this paper
• Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity

  2010cites this paper
• Stratégies thérapeutiques des cancers métastatiques RH+, HER2+ : trastuzumab, chimiothérapie, hormonothérapie

  2010cites this paper
• [Management of metastatic HER2-positive breast cancer: present and future].

  2010cites this paper
• Cancer du sein métastatique

  2009cites this paper
• Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.

  2009cites this paper
• Cost-effective analyses in Breast Cancer Research and Treatment

  2009cites this paper
• Breastcancer:beyondthecutting edge

  2009cites this paper
• Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study)

  2009cites this paper
• Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines.

  2009cites this paper
• Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.

  2009cites this paper
• Treatment options for breast cancer resistant to anthracycline and taxane.

  2009cites this paper
• Breast cancer: beyond the cutting edge

  2009cites this paper
• Cancer du sein métastatique

  2008cites this paper